Research

Articles

Kevin McKernan, Chief Scientific Officer and Founder of Medicinal Genomics, shares some insight behind his recently published paper related to cannabis trichomes and positive results on rapid yeast and mold plates.

New Research Shows that Cannabis Trichomes Trigger Positive Results on Rapid Yeast and Mold Plates

In his presentation for the psychedelics track at Cannabis Science Conference East 2022, James Schwartz, BSN, LNC, presented “A New Beginning for an Old Therapy: Case Series Review on the Treatment of PTSD and Other Psychiatric Disorders with Psilocybin and Other Psychedelics.” He reviewed the current research and clinical trials studying the effects of psilocybin, plus side effects, potential uses, latest trends, disorders currently being studied, and potential future applications. Schwartz was a trauma trained nurse who worked in the Trauma/Critical Care ICU at Oregon Health and Science University. He is an experienced medical legal consultant and CEO of Cascade High. Here are some highlights from his session.

Treating Psychiatric Disorders with Psychedelics: A Case Series Review at Cannabis Science Conference East 2022

A recent study disclosed how younger generations are experimenting with cannabis and hallucinogenic use at the highest levels according to data from previous years.

Cannabis and Hallucinogens Are Being Consumed at the Highest Rates on Record by Today’s Young Adults

In the work presented here, the authors pursue a more detailed understanding of the naturally rare occurring cannabinoid analogue, hexahydrocannabinol (HHC), by exploring the safety profile using a third-party lab to produce preclinical in vitro safety profile data. The purpose of these studies is to demonstrate HHC as a safe cannabinoid for potential human consumption.

Nonclinical In Vitro Safety Assessment Summary of Hemp Derived (R/S)-Hexahydrocannabinol ((R/S)-HHC)

This article examines why we should be studying the cannabinoids beyond THC and CBD in order to explore their potential medical value.

The Case for THCA and Other Minor Cannabinoids

Understanding the biochemical and physical process that comprise and control leaf-level physiology gives us deep insight into the plant, which may convert directly to cultivation practices.


Reading the Leaves: Adventures in the Leaf-Level  Physiology of Cannabis

Josh Crossney is the columnist and editor of “Cannabis Crossroads” and a contributing editor to 

 magazine. Crossney is also the president and CEO of Cannabis Science Conference. Direct correspondence to:


In this interview, Dr. David “Dedi” Meiri discusses his important work at Technion, challenges and opportunities in cannabis research, and a preview of his upcoming presentation for CSC East.

2022 CSC East Plenary Speaker Highlight: Dr. Dedi Meiri

is a Full Professor and Shimadzu Distinguished Professor of Analytical Chemistry in the Department of Chemistry & Biochemistry at The University of Texas (UT) at Arlington.

In the work presented here, the authors evaluated the effects of variable red-light exposure on the phytochemical content of four Group III cannabis cultivars.

Variable Red Light Exposure Affects Phytochemical Content  in Group III Cannabis Cultivars

View our interactive May/June 2022 digital edition.

May/June 2022 Digital Edition

In this interview, Donaghue Woodman, Head of Research and Development and Chief Medical Information Officer at Cannsun, provides an in-depth look at their current clinical trial on the effects of psilocybin in treating a prevalent yet unresolved issue in South Africa. 